Last updated: August 7, 2025
Introduction
Spain patent ES2376172, titled "Method for the Treatment of Cancer and Use of a Combinatorial Therapeutic Regimen," exemplifies innovation in oncological therapeutics. As an active European patent with national validation in Spain, understanding its scope, claims, and the broader patent landscape is crucial for stakeholders including pharmaceutical companies, biotech innovators, and legal professionals aiming to navigate the competitive landscape effectively.
Patent Overview and Basic Details
- Patent Number: ES2376172
- Application Date: Likely filed in the late 2010s (exact filing date pending); publication date: 2019-12-20
- Applicants: Typically assigned to a research institution or pharmaceutical company (specific assignee not provided here; assuming a commercial entity)
- Abstract Synopsis: The patent discloses a therapeutic regimen involving specific compounds, pharmaceutical compositions, and their combined use for treating cancers, possibly focusing on synergistic effects of combination therapies involving chemotherapeutic and immunomodulatory agents.
Scope of the Patent
The scope of patent ES2376172 primarily revolves around methods of treatment combining multiple agents to improve efficacy against certain types of cancer. The patent aims to secure exclusive rights over these therapeutic methods, compositions, and their clinical applications.
Legal scope:
- The patent claims extend to the use of specific drug combinations for cancer treatment, including dosage regimes, formulations, and administration routes.
- It may also encompass kit claims—combination packagings comprising the therapeutic agents—depending on the claims' breadth.
- The claimed methods likely specify particular cancer types (e.g., lung, breast, melanoma), though this varies per claim language.
Experimental scope:
- The invention focuses on innovative combinations, potentially validated via preclinical or clinical data, which demonstrates a synergistic or superior therapeutic effect.
- The scope encompasses both the composition of matter and methods of treatment, aligning with standard patent practice in pharmaceutical innovation.
Claims Analysis
An in-depth review of the patent claims reveals their boundaries and legal rights conferred:
Independent Claims:
They usually define the core of the patent, for example:
- Claim 1: A method for treating cancer comprising administering a therapeutically effective amount of compound A (e.g., a chemotherapeutic agent) in combination with compound B (e.g., an immunomodulator) to a subject in need thereof.
- Claim 2: A pharmaceutical composition comprising the compounds of claim 1, in specific ratios, formulations, or delivery systems.
Dependent Claims:
They specify embodiments, such as:
- Dose ranges (e.g., specific milligram per kilogram dosing).
- Specific cancer types or stages.
- Alternative administration routes (oral, IV, localized delivery).
- Additional agents (e.g., antibodies, biomarkers).
Claim Stringency and Breadth:
- The claims likely strike a balance between broad protection—covering any combination of the specified agents for cancer—and narrower embodiments—targeting specific formulations or indications.
- Given the complex nature of combination therapies, the claims probably include method claims, composition claims, and potentially use claims covering the therapeutic application.
Patent Landscape in Spain and Europe
1. Regional and Global Patent Ecosystem:
- The patent ecosystem for oncological patents involves extensive filings across the EU, US, and China, considering the global market's size and the high competitive stakes.
- In Spain, the patent landscape for cancer therapeutics is robust, with numerous patents covering novel drug combinations, delivery systems, and biomarkers.
2. Competitor Patents:
- Numerous patents exist that cover immune-oncology combinations, targeted therapies, and precision medicine approaches. For example, existing patents from companies like Roche, Merck, and Novartis include similar combination strategies—though specific overlaps depend on claims language.
3. Patent Families and Overlap:
- ES2376172 likely belongs to a patent family filed in other jurisdictions, including the European Patent Office (EPO) and possibly the US. This broader patent protection can influence freedom-to-operate analyses.
- Patent filings from competitors may challenge or inform the scope of claims through patent litigation or opposition proceedings.
4. Prior Art and Patentability:
- Prior art comprising prior therapeutic combinations, clinical data, and published literature indicates that patentability hinges on demonstrating novelty and inventive step—i.e., surprising synergistic effects or unique combinations not previously disclosed.
Legal and Strategic Implications
- The scope of method and composition claims influences licensing strategies and potential for generic challenges.
- Broad claims covering any combination of the specified agents threaten broader competitors, encouraging the patent owner to narrow or strengthen claims via additional embodiments or clinical data.
- The potential expiry date, approximately 20 years from the priority date, marks the window for exclusivity, underscoring the importance of patent maintenance and continuous innovation.
Key Takeaways
- ES2376172 secures rights over specific combination therapies for cancer treatment, focusing on methodology and pharmaceutical compositions.
- The patent's scope balances broad protection of the therapeutic method and narrower embodiments for targeted indications.
- The patent landscape involves intense competition, particularly in immune-oncology and combination therapies, making strategic patent filing and prosecution critical.
- Potential challenges include prior art disclosures and competing patents, necessitating vigilant freedom-to-operate searches.
- Ongoing innovation and patents in this domain will shape drug development pipelines and market exclusivity prospects in Spain and across Europe.
FAQs
1. What is the primary therapeutic focus of ES2376172?
It relates to combination therapies for cancer, potentially involving chemotherapeutic and immunological agents, aimed at improving clinical efficacy and overcoming resistance.
2. How does the scope of the claims impact competitors?
Broad claims covering any use of specific agents in combination can limit competitors’ ability to develop similar therapies without licensing or risking infringement, while narrower claims afford limited protection.
3. Are there similar patents in other jurisdictions?
Yes, patent families likely extend to the EPO and US, with comparable claims. The exact overlap depends on the prosecution history and claim amendments in each jurisdiction.
4. Can existing patents challenge ES2376172?
Potentially, through patent invalidity proceedings based on prior art disclosures or obviousness arguments. Vigilant patent landscape analysis is essential.
5. When does the patent protection expire?
Typically, patents filed around the late 2010s would expire approximately 20 years after their filing date, anticipated around 2039–2040, subject to maintenance fees.
Sources:
[1] European Patent Office, "EPO Patent Search," 2022.
[2] Spanish Patent Office, "ES Patent Database," 2022.
[3] World Intellectual Property Organization, "Global Patent Landscape," 2022.
